Published in Gastroenterol Hepatol (N Y) on January 01, 2012
Melatonin reduces ulcerative colitis-associated local and systemic damage in mice: investigation on possible mechanisms. Dig Dis Sci (2013) 1.52
Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis. Aliment Pharmacol Ther (2013) 0.94
Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis. Intest Res (2015) 0.89
Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial. Clin Exp Gastroenterol (2013) 0.87
Mucosal healing and fibrosis after acute or chronic inflammation in wild type FVB-N mice and C57BL6 procollagen α1(I)-promoter-GFP reporter mice. PLoS One (2012) 0.83
Trends and Factors Affecting Hospitalization Costs in Patients with Inflammatory Bowel Disease: A Two-Center Study over the Past Decade. Gastroenterol Res Pract (2013) 0.83
Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. PLoS One (2014) 0.83
Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience. BMC Gastroenterol (2014) 0.82
Raman spectroscopy of endoscopic colonic biopsies from patients with ulcerative colitis to identify mucosal inflammation and healing. Biomed Opt Express (2016) 0.81
Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy. PLoS One (2014) 0.79
Using a Treat-to-Target Management Strategy to Improve the Doctor-Patient Relationship in Inflammatory Bowel Disease. Am J Gastroenterol (2015) 0.78
Bin1: a new player in IBD barrier dysfunction. Dig Dis Sci (2012) 0.76
Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies. World J Gastroenterol (2017) 0.75
Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease. Inflamm Bowel Dis (2014) 0.75
Usefulness of Endoscopic Indices in Determination of Disease Activity in Patients with Crohn's Disease. Gastroenterol Res Pract (2016) 0.75
Mucosal healing effect of nilotinib in indomethacin-induced enterocolitis: A rat model. World J Gastroenterol (2015) 0.75
Capsule endoscopy in the diagnosis of Crohn's disease. Med Devices (Auckl) (2013) 0.75
Integrated Analysis of Biopsies from Inflammatory Bowel Disease Patients Identifies SAA1 as a Link Between Mucosal Microbes with TH17 and TH22 Cells. Inflamm Bowel Dis (2017) 0.75
Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J (1955) 19.22
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology (1976) 15.65
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Inflammatory bowel disease. N Engl J Med (2009) 8.62
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med (1987) 7.73
VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS. Br Med J (1964) 7.02
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
Predictability of the postoperative course of Crohn's disease. Gastroenterology (1990) 5.30
Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology (2007) 4.83
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology (2004) 4.45
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 4.39
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ (1989) 4.13
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc (2004) 4.12
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis (2010) 3.97
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med (2005) 3.56
5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology (1987) 3.35
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis (2011) 2.95
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology (1999) 2.80
Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol (2009) 2.80
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc (2006) 2.73
A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol (1978) 2.73
The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol (2009) 2.70
Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology (1990) 2.58
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis (2009) 2.33
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.32
Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol (2009) 2.27
Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis (2008) 2.22
Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology (1997) 2.18
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology (2002) 2.15
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology (2009) 2.09
Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol (2010) 2.07
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis (2008) 1.99
Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis (2010) 1.91
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut (2005) 1.84
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut (2006) 1.75
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol (2008) 1.70
Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis (2008) 1.69
Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis (2009) 1.65
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. Aliment Pharmacol Ther (2011) 1.63
Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy--feasibility study. Radiology (2003) 1.63
Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut (2004) 1.63
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol (2005) 1.59
A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology (2004) 1.51
A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology (2006) 1.39
Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis (2008) 1.36
Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis (2011) 1.29
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol (2007) 1.28
MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther (2007) 1.28
Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis (2008) 1.17
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis (2009) 1.14
Ulcerative colitis. An epidemiological study based on a regional inception cohort, with special reference to disease course and prognosis. Dan Med Bull (1999) 1.12
Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis (2009) 1.10
Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther (2006) 0.97
Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease. Clin Gastroenterol Hepatol (2011) 0.86
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83
Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (2008) 3.52
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol (2008) 3.30
Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology (2013) 3.28
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology (2003) 2.89
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol (2009) 2.80
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology (2002) 2.78
The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol (2009) 2.70
Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol (2010) 2.55
Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol (2012) 2.41
Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol (2008) 2.41
Rate of early/missed colorectal cancers after colonoscopy in older patients with or without inflammatory bowel disease in the United States. Am J Gastroenterol (2013) 2.39
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.32
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc (2008) 2.30
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis (2014) 2.19
Asthma and proinflammatory conditions: a population-based retrospective matched cohort study. Mayo Clin Proc (2012) 2.17
The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology (2013) 2.04
Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis (2007) 1.97
Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg (2007) 1.97
The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut (2006) 1.97
Retained Capsule Endoscopy in a Large Tertiary Care Academic Practice and Radiologic Predictors of Retention. Inflamm Bowel Dis (2015) 1.97
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol (2002) 1.89
Internet use by patients in an inflammatory bowel disease specialty clinic. Inflamm Bowel Dis (2007) 1.85
Geographical variability and environmental risk factors in inflammatory bowel disease. Gut (2013) 1.84
Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology (2002) 1.80
Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol (2012) 1.80
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology (2008) 1.78
Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med (2013) 1.71
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol (2008) 1.70
Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol (2004) 1.69
Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation. Radiology (2006) 1.60
Management of Crohn's disease of the ileoanal pouch with infliximab. Am J Gastroenterol (2003) 1.60
Hospitalisations and surgery in Crohn's disease. Gut (2012) 1.58
Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg (2010) 1.54
Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology (2010) 1.54
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol (2004) 1.51
Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology (2006) 1.51
Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates. Digestion (2006) 1.49
Fistulas to the urinary system in Crohn's disease: clinical features and outcomes. Am J Gastroenterol (2002) 1.45
Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: a case-control study. Inflamm Bowel Dis (2009) 1.42
Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis (2007) 1.39
Recurrence and impact of postoperative prophylaxis in laparoscopically treated primary ileocolic Crohn disease. Arch Surg (2010) 1.39
Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol (2012) 1.34
The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol (2002) 1.30
Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol (2004) 1.27
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis (2009) 1.25
Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis (2004) 1.22
Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 1.20
Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey. Inflamm Bowel Dis (2009) 1.19
Short CDAI: development and validation of a shortened and simplified Crohn's disease activity index. Inflamm Bowel Dis (2011) 1.18
The burden of inflammatory bowel disease in the United States: a moving target? Clin Gastroenterol Hepatol (2007) 1.17
The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol (2011) 1.15
Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis (2010) 1.13
Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol (2006) 1.13
Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology (2006) 1.12
Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am (2006) 1.12
Lymphocytic colitis: clinical features, treatment, and outcomes. Am J Gastroenterol (2002) 1.12
Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis (2006) 1.11
Early Crohn disease: a proposed definition for use in disease-modification trials. Gut (2010) 1.11
Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol (2007) 1.10
The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol (2004) 1.09
A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis (2013) 1.09
Small intestinal adenocarcinoma in Crohn's disease: a case-control study. Inflamm Bowel Dis (2004) 1.09
Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis (2006) 1.08
A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis (2006) 1.08
Incidence of spondyloarthropathy in patients with Crohn's disease: a population-based study. J Rheumatol (2012) 1.06
Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis (2009) 1.06
Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis (2006) 1.05
Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can J Gastroenterol (2011) 1.03
Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer. Am J Gastroenterol (2008) 1.02
Inflammatory bowel disease extending its reach. Gastroenterology (2005) 1.00
Diagnostic advances in inflammatory bowel disease (imaging and laboratory). Curr Gastroenterol Rep (2009) 1.00
Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study. Am J Gastroenterol (2013) 1.00
Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes. Inflamm Bowel Dis (2005) 0.99
Evolving diagnostic strategies for inflammatory bowel disease. Curr Gastroenterol Rep (2006) 0.99
Detection of Cytomegalovirus in Patients with Inflammatory Bowel Disease: Where to Biopsy and How Many Biopsies? Inflamm Bowel Dis (2015) 0.99
Cancer risk in celiac disease. Gastroenterology (2002) 0.98
Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy. Inflamm Bowel Dis (2011) 0.98
Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis (2010) 0.98
Safety profile of IBD therapeutics: infectious risks. Gastroenterol Clin North Am (2009) 0.98
Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography. Inflamm Bowel Dis (2008) 0.98
Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis (2013) 0.97
Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis (2002) 0.97
Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics. Inflamm Bowel Dis (2013) 0.97
Similar outcomes of surgical and medical treatment of intra-abdominal abscesses in patients with Crohn's disease. Clin Gastroenterol Hepatol (2011) 0.96
Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am J Gastroenterol (2010) 0.96
Procedure time and the determination of polypoid abnormalities with experience: implementation of a chromoendoscopy program for surveillance colonoscopy for ulcerative colitis. Inflamm Bowel Dis (2013) 0.95
Benefit of computed tomography enterography in Crohn's disease: effects on patient management and physician level of confidence. Inflamm Bowel Dis (2011) 0.93
CT enterography and fistulizing Crohn's disease: clinical benefit and radiographic findings. Abdom Imaging (2009) 0.93
Appendiceal skip inflammation and ulcerative colitis. Dig Dis Sci (2014) 0.92
Infliximab for Crohn's disease: the first 500 patients followed up through 2009. Dig Dis Sci (2012) 0.92
Racial/Ethnic and regional differences in the prevalence of inflammatory bowel disease in the United States. Digestion (2013) 0.92
Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis (2013) 0.92
Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis (2002) 0.92
Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease. Inflamm Bowel Dis (2011) 0.90